We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Shaky prognosis

23 June 2021 By Aimee Donnellan

The $100 bln pharma group set a 5% sales growth target for its new medicines business. Offloading 80% of the consumer unit and loading it up with debt creates an $11 bln war chest, too. But both GSK’s drug pipeline and its under-fire CEO need to deliver for the new plan to work.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)